There was a significant trend toward increased tumor burden with increasing Rap1 KI dosage from WT to Rap1WT/KI to Rap1KI/KI and a significant increase in tumor incidence in Rap1KI/KI mice, with a prevalence for tumor formation in the liver and spleen (Fig 6C and S5 Table). This evidence concerns the gene TERF2IP and neoplasm.